Menu

Patient resources and product support

Takeda is proud to provide a variety of programs and resources for patients with hemophilia

Takeda’s CoPay Assistance Program offers financial assistance to eligible patients.

FREEDOM OF CHOICE™

Your patients may be eligible to receive 15 free doses of FEIBA®. This Free Trial Program is for new FEIBA patients only. Participants must receive consultation and approval from a healthcare provider.

Download Registration Form

Hematology Support Center

Takeda's Hematology Support Center (HSC) is dedicated to helping patients who have been prescribed Takeda hematology products and healthcare providers who have a patient on or ready to start on a Takeda hematology product. HSC offers help with treatment access, as well as educational resources and information on financial assistance programs.
Call 1-888-229-8379 Monday—Friday 8:30AM—8:00PM (ET).

Hematology Support Logo.
Visit HematologySupport.com

If you have patients that have been prescribed FEIBA, here are a few ways that the HSC can help:

  • Case managers checklist icon.

    Case Managers

    A point of contact who is ready to assist your patients with accessing their treatment

  • CoPay assistance icon.

    CoPay Assistance

    For eligible commercially insured Takeda patients, Takeda's CoPay Assistance Program covers out-of-pocket expenses related to a patient's Takeda Hematology treatment for which there is a co-pay, such as deductibles and coinsurances†‡§

  • Patient Access Manager icon.

    Patient Access Manager

    A Patient Access Manager is available and can provide one-on-one, personalized insurance education and access information

  • Resources and Education icon.

    Resources and Education

    Connecting patients and their caregivers with educational resources ‐ including a Healthcare Educator who can work with them one-on-one if needed

  • Must meet specific program eligibility requirements and terms and conditions. Certain restrictions apply. Not all Takeda hematology products are available for each program.
  • These programs are not valid for prescriptions reimbursed, in whole or in part by Medicaid, Medicare, Medigap, VA, DoD, TRICARE or any other federal or state healthcare programs, including state pharmaceutical assistance programs, and where prohibited by health insurance provider or by law. Offer good only in the United States. Offer void where prohibited by law, taxed, or restricted. Takeda reserves the right to rescind, revoke or amend each offer at any time without notice.
  • §
    Non-medication expenses, such as ancillary supplies or certain/some administration-related costs, are not eligible.

Specialized patient education

Additional Takeda team members are available for more specialized assistance:

  • Bilingual Community Educators (BCEs): Takeda's BCE teams can assist patients and caregivers for whom English is a second language

Got questions? A Takeda rep can help

A Local Takeda Representative is available to connect with you and help answer your questions about FEIBA.

Find a Local Takeda Rep
See LessMore

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,

Indications for Feiba

FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in
hemophilia A and B patients with inhibitors for:

  • Control and prevention of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

FEIBA is not indicated for the treatment of bleeding episodes resulting from...

Detailed Important Risk Information

WARNING: EMBOLIC AND THROMBOTIC EVENTS

  • Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
  • Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;